CARDIOVASCULAR OUTCOMES
The primary composite outcome in EMPA-REG, LEADER, and SUSTAIN-6 was death from cardiovascular causes, nonfatal MI, or nonfatal stroke, whereas Look AHEAD also included hospitalization for angina. When hospitalization for angina was added to EMPA-REG's primary composite outcome (a prespecified secondary outcome), the advantage of empagliflozin over placebo was no longer significant (P=0.08).
Comparison of individual components of the composite primary end points among the trials shows only modest reductions in nonfatal MI that did not achieve statistical significance in any of the trials (Table) . Although none of the trials showed a reduction in nonfatal MI, reductions in total mortality were achieved in both EMPA-REG (hazard ratio [HR] , 0.68; 95% confidence interval [CI] , 0.57-0.82; P<0.001) and LEADER (HR, 0.85; 95% CI, 0.74-0.97; P=0.02), with a similar reduction observed in Look AHEAD (HR, 0.85; 95% CI, 0.69-1.04; P=0.11) that did not achieve statistical significance. The unexpected findings of reduction in total and cardiovascular mortality without similar reduction in nonfatal MI has led to increased interest in outcomes beyond atherothrombotic coronary events. The most striking benefit observed in EMPA-REG was for heart failure hospitalization (HR, 0.65; 95% CI, 0. 
PATIENT POPULATIONS
Cardiovascular event (CVE) risk in diabetes mellitus is not homogeneous. Differences in risk dictate the intensity of preventive therapy in current guidelines and the timeline of expected benefits. In contrast to the pharmacotherapy studies, the eligibility criteria in Look AHEAD resulted in the selection of a low-risk cohort. All Look AHEAD participants were required to pass an exercise stress test before enrollment, yielding a sample with a very low 10-year CVE risk. Only 14% of Look AHEAD participants reported a history of CVD at baseline, and enrollment was deferred at least 3 months after their most recent CVE. Look AHEAD participants were younger and had better glucose control, shorter diabetes history, and lower smoking prevalence than participants in the other studies, and did not have significant renal insufficiency. In contrast, the pharmacotherapy trials recruited individuals with clear clinical indicators of increased CVE and mortality risk. In EMPA-REG, a positive stress test was one of the criteria for inclusion, and >99% of participants had established CVD. Three-fourths of EMPA-REG participants and a quarter of LEADER and SUSTAIN-6 participants had moderate/severe renal insufficiency, and participants in the respective trials could enroll 2 months, 14 days, or 3 months after their most recent CVE. A recent post hoc analysis of Look AHEAD examined weight loss and fitness in the entire cohort (ie, both treatment groups combined). 5 Individuals who lost at least 10% of body weight in the first year had a 21% lower risk for the primary outcome (adjusted HR, 0.79; 95% CI, 0.64-0.98; P=0.03) and a 31% reduction for a secondary outcome of cardiovascular death, MI, and stroke (adjusted HR, 0.69; 95% CI, 0.53-0.91; P<0.05). Individuals who improved fitness by 2 metabolic equivalents had a similar but nonsignificant 22% reduction in the primary end point (adjusted HR, 0.78; 95% CI, 0.60-1.03; P=0.079) and a 41% reduction in cardiovascular death, MI, and stroke (adjusted HR, 0.59; 95% CI, 0. Data for participant characteristics shown as mean, unless otherwise specified, and prevalence rounded to whole numbers. Event rate per 1000 patient-years shown in treatment arm versus control arm, respectively. BMI indicates body mass index; BP, blood pressure; CI, confidence interval; HbA1c, hemoglobin A1c; and NR, not reported. *In the LEADER and SUSTAIN-6 trials, prespecified secondary outcomes were considered exploratory and P values were not adjusted for multiplicity. †In SUSTAIN-6, only nonfatal stroke was reported. ‡Median duration. 
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